Barclays PLC Aerovate Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 18,972 shares of AVTE stock, worth $49,896. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,972

Previous 18,972 -0.0%

Holding current value

$49,896

Previous $39,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$1.61 - $2.09 $23,109 - $29,999	14,354 Added 310.83%	18,972 $39,000
Q2 2024 Aug 14, 2024	SELL	$1.41 - $30.75 $4,588 - $100,060	-3,254 Reduced 41.34%	4,618 $8,000
Q1 2024 May 15, 2024	SELL	$17.68 - $29.57 $132,988 - $222,425	-7,522 Reduced 48.86%	7,872 $233,000
Q4 2023 Feb 15, 2024	BUY	$9.58 - $24.25 $110,629 - $280,039	11,548 Added 300.26%	15,394 $348,000
Q3 2023 Nov 07, 2023	BUY	$12.9 - $18.88 $5,676 - $8,307	440 Added 12.92%	3,846 $52,000
Q2 2023 Aug 03, 2023	SELL	$15.63 - $22.01 $20,537 - $28,921	-1,314 Reduced 27.84%	3,406 $58,000
Q1 2023 May 04, 2023	BUY	$19.17 - $27.7 $16,294 - $23,545	850 Added 21.96%	4,720 $94,000
Q4 2022 Feb 13, 2023	BUY	$15.92 - $30.52 $55,417 - $106,240	3,481 Added 894.86%	3,870 $113,000
Q3 2022 Nov 03, 2022	SELL	$14.77 - $25.79 $53,688 - $93,746	-3,635 Reduced 90.33%	389 $6,000
Q2 2022 Aug 12, 2022	SELL	$10.8 - $16.91 $19,040 - $29,812	-1,763 Reduced 30.46%	4,024 $63,000
Q1 2022 May 16, 2022	BUY	$8.25 - $18.33 $47,742 - $106,075	5,787 New	5,787 $105,000

Others Institutions Holding AVTE

# of Institutions

Shares Held

28.1M

Call Options Held

116K

Put Options Held

26.6K

View Full List

About Aerovate Therapeutics, Inc.

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $64.3M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

More about AVTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account